Faes Livia, Bijon Jacques, Bacci Tommaso, Freund K Bailey
Vitreous Retina Macula Consultants of New York, New York, USA.
Ophthalmology Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena University Hospital, Siena, Italy.
Eye (Lond). 2025 Apr;39(5):870-882. doi: 10.1038/s41433-024-03343-3. Epub 2024 Oct 11.
Type 3 macular neovascularization (MNV) is a unique form of neovascular age-related macular degeneration (AMD) that presents distinct pathogenetic features, clinical manifestations, and prognostic considerations when compared to types 1 and 2 MNV. Insights gained from clinicopathological correlations, bridging in vivo examination techniques with ex vivo histological analysis, have significantly enhanced our comprehension of this MNV phenotype, shaped current management strategies and influenced future directions for therapeutics. The particularities of type 3 MNV, which may largely stem from its origin from the retinal vasculature, are critically important for predicting the disease course. Our current understanding suggests that type 3 MNV occurs in response to retinal pigment epithelium (RPE) disruption and photoreceptor loss when neovessels originating from the deep capillary plexus are accompanied by activated Müller glia as they infiltrate sub-retinal pigment epithelium basal laminar deposits. Dysregulation of angiogenic and angiostatic factors are thought to play a key role in its pathogenesis. The prognosis for type 3 MNV is likely bilateral involvement and progression towards macular atrophy. It may be imperative for practitioners to distinguish type 3 MNV from other mimicking pathologies such as intraretinal microvascular anomalies, which are also part of the type 3 disease spectrum. For instance, deep retinal age-related microvascular anomalies (DRAMA) may present with similar features on multimodal imaging yet may necessitate distinct management protocols. Distinguishing between these conditions may be vital for implementing tailored treatment regimens and improving patient outcomes in the diverse landscape of AMD phenotypes in the future.
3型黄斑新生血管(MNV)是年龄相关性黄斑变性(AMD)的一种独特形式,与1型和2型MNV相比,具有不同的发病机制、临床表现和预后因素。通过临床病理相关性研究,将体内检查技术与体外组织学分析相结合,显著加深了我们对这种MNV表型的理解,塑造了当前的治疗策略,并影响了未来的治疗方向。3型MNV的特殊性可能主要源于其起源于视网膜血管系统,这对于预测疾病进程至关重要。我们目前的认识表明,当起源于深层毛细血管丛的新生血管在浸润视网膜色素上皮(RPE)下基底膜沉积物时伴有活化的Müller胶质细胞,3型MNV会在RPE破坏和光感受器丧失的情况下发生。血管生成和血管抑制因子的失调被认为在其发病机制中起关键作用。3型MNV的预后可能是双侧受累并进展为黄斑萎缩。从业者必须将3型MNV与其他类似病变(如视网膜内微血管异常)区分开来,后者也是3型疾病谱的一部分。例如,深部视网膜年龄相关性微血管异常(DRAMA)在多模态成像上可能表现出相似的特征,但可能需要不同的管理方案。在未来AMD表型的多样化情况下,区分这些情况对于实施个性化治疗方案和改善患者预后可能至关重要。